In contrast, the prevalence of established CVD was 73100% in other CVOTs ( Thus, overall, GLP-1RAs appear to have the potential for beneficial effects on adverse CV outcomes, especially concerning ischemic events and related mortality
Keep a detailed record of your diet, exercise, and any other relevant factors

When semaglutide may be preferred Established cardiovascular disease SELECT trial provides cardiovascular mortality data that tirzepatides SURMOUNT-MMO cannot yet match When an oral option is important Rybelsus (oral semaglutide) has no tirzepatide equivalent Prior tolerance established for patients already on Ozempic who are transitioning to a weight management indication Insurance coverage specifically for Wegovy when Zepbound is not covered When tirzepatide may be preferred Maximum weight loss is the primary goal tirzepatide consistently produces larger average weight loss Type 2 diabetes with significant HbA1c reduction needed tirzepatide outperforms semaglutide on glycemic endpoints Prior GI intolerance on semaglutide some patients tolerate tirzepatide better, though this is individual Cost Zepbounds list price is modestly lower than Wegovy, and Eli Lillys self-pay vial program may offer better access for uninsured patients When the choice doesnt matter much For patients who respond well to either drug at therapeutic doses, the practical difference in outcome may be smaller than the trial averages suggest

Fisiu ALC zmniejsza uszkodzenie organizmu spowodowane niedotlenieniem, wzmacnia ukad odpornociowy, chroni przed stresem oksydacyjnym, stymuluje aktywno antyoksydacyjn niektrych enzymw, chroni bony komrkowe, zwalnia procesy starzenia mzgu
The gap between those two figures is where most unpleasant surprises live